Evidence map›Paper›PMID 39802487›Full record

ArticleGastro hep advances2025

Activated CD27

Tessa Dieckman, Mette Schreurs, Ciska Lindelauf, Ahmed Mahfouz, Caroline R Meijer, Louise Pigeaud, Vincent van Unen, Gerd Bouma, Frits Koning

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tessa DieckmanDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Mette SchreursDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Ciska LindelaufDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Ahmed MahfouzDelft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands.
Caroline R MeijerDepartment of Paediatrics, Willem Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Louise PigeaudDepartment of Paediatrics, Willem Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Vincent van UnenDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Gerd BoumaDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands.
Frits KoningDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Refractory celiac disease type II (RCDII) is characterized by a clonally expanded aberrant cell population in the small intestine. The role of other tissue-resident immune subsets in RCDII is unknown. Here, we characterized CD8 and CD4 T cells in RCDII duodenum at the single-cell level and Methods: We applied mass cytometry on CD45 Results: Compared to healthy controls, we observed that CD27 Conclusion: RCDII is characterized by the simultaneous presence of an activated CD27

Indexed as

CoeliacEnteropathy-associated T cell lymphomaGluten enteropathySingle-cell analysis

Identifiers

PMID39802487
PMCPMC11719358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.